Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)
Background Epidemiological studies substantiated that subjects with elevated lipoprotein(a) [Lp(a)] have a markedly increased cardiovascular risk. Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) lowers both LDL cholesterol (LDL-C) as well as Lp(a), albeit modestly. Effects of PCS...
Gespeichert in:
| Veröffentlicht in: | Lipids in health and disease 2020-05, Vol.19 (1), p.91-91, Article 91 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 91 |
|---|---|
| container_issue | 1 |
| container_start_page | 91 |
| container_title | Lipids in health and disease |
| container_volume | 19 |
| creator | Zhang, Xiang Stiekema, Lotte C. A. Stroes, Erik S. G. Groen, Albert K. |
| description | Background Epidemiological studies substantiated that subjects with elevated lipoprotein(a) [Lp(a)] have a markedly increased cardiovascular risk. Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) lowers both LDL cholesterol (LDL-C) as well as Lp(a), albeit modestly. Effects of PCSK9 inhibition on circulating metabolites such as lipoprotein subclasses, amino acids and fatty acids remain to be characterized. Methods We performed nuclear magnetic resonance (NMR) metabolomics on plasma samples derived from 30 individuals with elevated Lp(a) (> 150 mg/dL). The 30 participants were randomly assigned into two groups, placebo (N = 14) and evolocumab (N = 16). We assessed the effect of 16 weeks of evolocumab 420 mg Q4W treatment on circulating metabolites by running lognormal regression analyses, and compared this to placebo. Subsequently, we assessed the interrelationship between Lp(a) and 14 lipoprotein subclasses in response to treatment with evolocumab, by running multilevel multivariate regression analyses. Results On average, evolocumab treatment for 16 weeks resulted in a 17% (95% credible interval: 8 to 26%, P < 0.001) reduction of circulating Lp(a), coupled with substantial reduction of VLDL, IDL and LDL particles as well as their lipid contents. Interestingly, increasing concentrations of baseline Lp(a) were associated with larger reduction in triglyceride-rich VLDL particles after evolocumab treatment. Conclusions Inhibition of PCSK9 with evolocumab markedly reduced VLDL particle concentrations in addition to lowering LDL-C. The extent of reduction in VLDL particles depended on the baseline level of Lp(a). Our findings suggest a marked effect of evolocumab on VLDL metabolism in subjects with elevated Lp(a). |
| doi_str_mv | 10.1186/s12944-020-01280-0 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2404425562</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A627444250</galeid><doaj_id>oai_doaj_org_article_304998e60c55467cab6966bfd00b82d0</doaj_id><sourcerecordid>A627444250</sourcerecordid><originalsourceid>FETCH-LOGICAL-c563t-db5fc8fe794fbe68a634b56941bb2e39a59dc38a558c2f7b5fd8acd0f2287a2e3</originalsourceid><addsrcrecordid>eNqNkl9rFDEUxQdRbK1-AR9kwJeKTE0ySSZ5EcpStbiioAXfQpK52c0yO1knmS1-ezO7de2KDxJILrm_c_KHUxTPMbrAWPA3ERNJaYUIqhAmIs8PilNMG14xjL8_vFefFE9iXKFMNpw_Lk5qUsuaMHJa3HyCpE3ovC3BObAplsGVX2ZfP8rS90tvfPKhL299WpZX29AFO661ya0yjma143c96GCrE7TlfHOuXz0tHjndRXh2t54VN--uvs0-VPPP769nl_PKMl6nqjXMWeGgkdQZ4ELzmhrGJcXGEKilZrK1tdCMCUtck-lWaNsiR4hodCbOiuu9bxv0Sm0Gv9bDTxW0V7uNMCyUHpK3HagaUSkFcGQZo7yx2nDJuXEtQkaQFmWvt3uvzWjW0Fro06C7I9PjTu-XahG2qiGYc4qzwfmdwRB-jBCTWvtooet0D2GMilCEBW5qQjP68i90Fcahz181UZQSxjj5Qy10foDvXcjn2slUXXLS0Imb7n3xDyqPFtbehh6cz_tHArIX2CHEOIA7vBEjNQVL7YOlclzULlhqEr24_zsHye8kZUDsgVswwUXrobdwwBBCrKZECpYrhGc-6SlXszD2KUtf_7-0_gXmJ-eq</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2404425562</pqid></control><display><type>article</type><title>Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)</title><source>MEDLINE</source><source>Springer Online Journals Complete</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>PubMed Central</source><source>Springer Nature OA/Free Journals</source><source>Free Full-Text Journals in Chemistry</source><creator>Zhang, Xiang ; Stiekema, Lotte C. A. ; Stroes, Erik S. G. ; Groen, Albert K.</creator><creatorcontrib>Zhang, Xiang ; Stiekema, Lotte C. A. ; Stroes, Erik S. G. ; Groen, Albert K.</creatorcontrib><description>Background Epidemiological studies substantiated that subjects with elevated lipoprotein(a) [Lp(a)] have a markedly increased cardiovascular risk. Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) lowers both LDL cholesterol (LDL-C) as well as Lp(a), albeit modestly. Effects of PCSK9 inhibition on circulating metabolites such as lipoprotein subclasses, amino acids and fatty acids remain to be characterized. Methods We performed nuclear magnetic resonance (NMR) metabolomics on plasma samples derived from 30 individuals with elevated Lp(a) (> 150 mg/dL). The 30 participants were randomly assigned into two groups, placebo (N = 14) and evolocumab (N = 16). We assessed the effect of 16 weeks of evolocumab 420 mg Q4W treatment on circulating metabolites by running lognormal regression analyses, and compared this to placebo. Subsequently, we assessed the interrelationship between Lp(a) and 14 lipoprotein subclasses in response to treatment with evolocumab, by running multilevel multivariate regression analyses. Results On average, evolocumab treatment for 16 weeks resulted in a 17% (95% credible interval: 8 to 26%, P < 0.001) reduction of circulating Lp(a), coupled with substantial reduction of VLDL, IDL and LDL particles as well as their lipid contents. Interestingly, increasing concentrations of baseline Lp(a) were associated with larger reduction in triglyceride-rich VLDL particles after evolocumab treatment. Conclusions Inhibition of PCSK9 with evolocumab markedly reduced VLDL particle concentrations in addition to lowering LDL-C. The extent of reduction in VLDL particles depended on the baseline level of Lp(a). Our findings suggest a marked effect of evolocumab on VLDL metabolism in subjects with elevated Lp(a).</description><identifier>ISSN: 1476-511X</identifier><identifier>EISSN: 1476-511X</identifier><identifier>DOI: 10.1186/s12944-020-01280-0</identifier><identifier>PMID: 32393252</identifier><language>eng</language><publisher>LONDON: Springer Nature</publisher><subject><![CDATA[Aged ; Amino acids ; Analysis ; Antibodies, Monoclonal, Humanized - therapeutic use ; Apolipoproteins ; Biochemistry & Molecular Biology ; Cardiovascular diseases ; Cholesterol ; Cholesterol, HDL - blood ; Cholesterol, LDL - antagonists & inhibitors ; Cholesterol, LDL - blood ; Cholesterol, VLDL - antagonists & inhibitors ; Cholesterol, VLDL - blood ; Clinical trials ; Drug dosages ; Epidemiology ; Evolocumab ; Fasting ; Fatty acids ; Female ; Gene Expression ; Heart surgery ; Humans ; Hyperlipidemias - blood ; Hyperlipidemias - diagnosis ; Hyperlipidemias - drug therapy ; Hyperlipidemias - genetics ; Hypolipidemic Agents - therapeutic use ; Kexin ; Life Sciences & Biomedicine ; Lipid Metabolism - drug effects ; Lipids ; Lipoprotein A ; Lipoprotein(a) - antagonists & inhibitors ; Lipoprotein(a) - blood ; Lipoproteins ; Lipoproteins (very low density) ; Low density lipoprotein ; Low density lipoproteins ; Magnetic Resonance Spectroscopy ; Male ; Metabolism ; Metabolites ; Metabolome ; Metabolomics ; Middle Aged ; Monoclonal antibodies ; Multivariate Analysis ; NMR ; Nonsteroidal anti-inflammatory drugs ; Nuclear magnetic resonance ; Nutrition & Dietetics ; Patients ; PCSK9 antibodies ; PCSK9 Inhibitors ; Proprotein Convertase 9 - blood ; Proprotein Convertase 9 - genetics ; Proprotein convertases ; Science & Technology ; Substance abuse treatment ; Subtilisin ; Trans fatty acids ; Triglycerides ; Triglycerides - antagonists & inhibitors ; Triglycerides - blood ; Variables ; VLDL]]></subject><ispartof>Lipids in health and disease, 2020-05, Vol.19 (1), p.91-91, Article 91</ispartof><rights>COPYRIGHT 2020 BioMed Central Ltd.</rights><rights>2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>5</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000534298500001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c563t-db5fc8fe794fbe68a634b56941bb2e39a59dc38a558c2f7b5fd8acd0f2287a2e3</citedby><cites>FETCH-LOGICAL-c563t-db5fc8fe794fbe68a634b56941bb2e39a59dc38a558c2f7b5fd8acd0f2287a2e3</cites><orcidid>0000-0002-3878-9196</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216641/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216641/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,2103,2115,27929,27930,28253,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32393252$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Xiang</creatorcontrib><creatorcontrib>Stiekema, Lotte C. A.</creatorcontrib><creatorcontrib>Stroes, Erik S. G.</creatorcontrib><creatorcontrib>Groen, Albert K.</creatorcontrib><title>Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)</title><title>Lipids in health and disease</title><addtitle>LIPIDS HEALTH DIS</addtitle><addtitle>Lipids Health Dis</addtitle><description>Background Epidemiological studies substantiated that subjects with elevated lipoprotein(a) [Lp(a)] have a markedly increased cardiovascular risk. Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) lowers both LDL cholesterol (LDL-C) as well as Lp(a), albeit modestly. Effects of PCSK9 inhibition on circulating metabolites such as lipoprotein subclasses, amino acids and fatty acids remain to be characterized. Methods We performed nuclear magnetic resonance (NMR) metabolomics on plasma samples derived from 30 individuals with elevated Lp(a) (> 150 mg/dL). The 30 participants were randomly assigned into two groups, placebo (N = 14) and evolocumab (N = 16). We assessed the effect of 16 weeks of evolocumab 420 mg Q4W treatment on circulating metabolites by running lognormal regression analyses, and compared this to placebo. Subsequently, we assessed the interrelationship between Lp(a) and 14 lipoprotein subclasses in response to treatment with evolocumab, by running multilevel multivariate regression analyses. Results On average, evolocumab treatment for 16 weeks resulted in a 17% (95% credible interval: 8 to 26%, P < 0.001) reduction of circulating Lp(a), coupled with substantial reduction of VLDL, IDL and LDL particles as well as their lipid contents. Interestingly, increasing concentrations of baseline Lp(a) were associated with larger reduction in triglyceride-rich VLDL particles after evolocumab treatment. Conclusions Inhibition of PCSK9 with evolocumab markedly reduced VLDL particle concentrations in addition to lowering LDL-C. The extent of reduction in VLDL particles depended on the baseline level of Lp(a). Our findings suggest a marked effect of evolocumab on VLDL metabolism in subjects with elevated Lp(a).</description><subject>Aged</subject><subject>Amino acids</subject><subject>Analysis</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Apolipoproteins</subject><subject>Biochemistry & Molecular Biology</subject><subject>Cardiovascular diseases</subject><subject>Cholesterol</subject><subject>Cholesterol, HDL - blood</subject><subject>Cholesterol, LDL - antagonists & inhibitors</subject><subject>Cholesterol, LDL - blood</subject><subject>Cholesterol, VLDL - antagonists & inhibitors</subject><subject>Cholesterol, VLDL - blood</subject><subject>Clinical trials</subject><subject>Drug dosages</subject><subject>Epidemiology</subject><subject>Evolocumab</subject><subject>Fasting</subject><subject>Fatty acids</subject><subject>Female</subject><subject>Gene Expression</subject><subject>Heart surgery</subject><subject>Humans</subject><subject>Hyperlipidemias - blood</subject><subject>Hyperlipidemias - diagnosis</subject><subject>Hyperlipidemias - drug therapy</subject><subject>Hyperlipidemias - genetics</subject><subject>Hypolipidemic Agents - therapeutic use</subject><subject>Kexin</subject><subject>Life Sciences & Biomedicine</subject><subject>Lipid Metabolism - drug effects</subject><subject>Lipids</subject><subject>Lipoprotein A</subject><subject>Lipoprotein(a) - antagonists & inhibitors</subject><subject>Lipoprotein(a) - blood</subject><subject>Lipoproteins</subject><subject>Lipoproteins (very low density)</subject><subject>Low density lipoprotein</subject><subject>Low density lipoproteins</subject><subject>Magnetic Resonance Spectroscopy</subject><subject>Male</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Metabolome</subject><subject>Metabolomics</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Multivariate Analysis</subject><subject>NMR</subject><subject>Nonsteroidal anti-inflammatory drugs</subject><subject>Nuclear magnetic resonance</subject><subject>Nutrition & Dietetics</subject><subject>Patients</subject><subject>PCSK9 antibodies</subject><subject>PCSK9 Inhibitors</subject><subject>Proprotein Convertase 9 - blood</subject><subject>Proprotein Convertase 9 - genetics</subject><subject>Proprotein convertases</subject><subject>Science & Technology</subject><subject>Substance abuse treatment</subject><subject>Subtilisin</subject><subject>Trans fatty acids</subject><subject>Triglycerides</subject><subject>Triglycerides - antagonists & inhibitors</subject><subject>Triglycerides - blood</subject><subject>Variables</subject><subject>VLDL</subject><issn>1476-511X</issn><issn>1476-511X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNkl9rFDEUxQdRbK1-AR9kwJeKTE0ySSZ5EcpStbiioAXfQpK52c0yO1knmS1-ezO7de2KDxJILrm_c_KHUxTPMbrAWPA3ERNJaYUIqhAmIs8PilNMG14xjL8_vFefFE9iXKFMNpw_Lk5qUsuaMHJa3HyCpE3ovC3BObAplsGVX2ZfP8rS90tvfPKhL299WpZX29AFO661ya0yjma143c96GCrE7TlfHOuXz0tHjndRXh2t54VN--uvs0-VPPP769nl_PKMl6nqjXMWeGgkdQZ4ELzmhrGJcXGEKilZrK1tdCMCUtck-lWaNsiR4hodCbOiuu9bxv0Sm0Gv9bDTxW0V7uNMCyUHpK3HagaUSkFcGQZo7yx2nDJuXEtQkaQFmWvt3uvzWjW0Fro06C7I9PjTu-XahG2qiGYc4qzwfmdwRB-jBCTWvtooet0D2GMilCEBW5qQjP68i90Fcahz181UZQSxjj5Qy10foDvXcjn2slUXXLS0Imb7n3xDyqPFtbehh6cz_tHArIX2CHEOIA7vBEjNQVL7YOlclzULlhqEr24_zsHye8kZUDsgVswwUXrobdwwBBCrKZECpYrhGc-6SlXszD2KUtf_7-0_gXmJ-eq</recordid><startdate>20200511</startdate><enddate>20200511</enddate><creator>Zhang, Xiang</creator><creator>Stiekema, Lotte C. A.</creator><creator>Stroes, Erik S. G.</creator><creator>Groen, Albert K.</creator><general>Springer Nature</general><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-3878-9196</orcidid></search><sort><creationdate>20200511</creationdate><title>Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)</title><author>Zhang, Xiang ; Stiekema, Lotte C. A. ; Stroes, Erik S. G. ; Groen, Albert K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c563t-db5fc8fe794fbe68a634b56941bb2e39a59dc38a558c2f7b5fd8acd0f2287a2e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aged</topic><topic>Amino acids</topic><topic>Analysis</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Apolipoproteins</topic><topic>Biochemistry & Molecular Biology</topic><topic>Cardiovascular diseases</topic><topic>Cholesterol</topic><topic>Cholesterol, HDL - blood</topic><topic>Cholesterol, LDL - antagonists & inhibitors</topic><topic>Cholesterol, LDL - blood</topic><topic>Cholesterol, VLDL - antagonists & inhibitors</topic><topic>Cholesterol, VLDL - blood</topic><topic>Clinical trials</topic><topic>Drug dosages</topic><topic>Epidemiology</topic><topic>Evolocumab</topic><topic>Fasting</topic><topic>Fatty acids</topic><topic>Female</topic><topic>Gene Expression</topic><topic>Heart surgery</topic><topic>Humans</topic><topic>Hyperlipidemias - blood</topic><topic>Hyperlipidemias - diagnosis</topic><topic>Hyperlipidemias - drug therapy</topic><topic>Hyperlipidemias - genetics</topic><topic>Hypolipidemic Agents - therapeutic use</topic><topic>Kexin</topic><topic>Life Sciences & Biomedicine</topic><topic>Lipid Metabolism - drug effects</topic><topic>Lipids</topic><topic>Lipoprotein A</topic><topic>Lipoprotein(a) - antagonists & inhibitors</topic><topic>Lipoprotein(a) - blood</topic><topic>Lipoproteins</topic><topic>Lipoproteins (very low density)</topic><topic>Low density lipoprotein</topic><topic>Low density lipoproteins</topic><topic>Magnetic Resonance Spectroscopy</topic><topic>Male</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Metabolome</topic><topic>Metabolomics</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Multivariate Analysis</topic><topic>NMR</topic><topic>Nonsteroidal anti-inflammatory drugs</topic><topic>Nuclear magnetic resonance</topic><topic>Nutrition & Dietetics</topic><topic>Patients</topic><topic>PCSK9 antibodies</topic><topic>PCSK9 Inhibitors</topic><topic>Proprotein Convertase 9 - blood</topic><topic>Proprotein Convertase 9 - genetics</topic><topic>Proprotein convertases</topic><topic>Science & Technology</topic><topic>Substance abuse treatment</topic><topic>Subtilisin</topic><topic>Trans fatty acids</topic><topic>Triglycerides</topic><topic>Triglycerides - antagonists & inhibitors</topic><topic>Triglycerides - blood</topic><topic>Variables</topic><topic>VLDL</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Xiang</creatorcontrib><creatorcontrib>Stiekema, Lotte C. A.</creatorcontrib><creatorcontrib>Stroes, Erik S. G.</creatorcontrib><creatorcontrib>Groen, Albert K.</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Lipids in health and disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Xiang</au><au>Stiekema, Lotte C. A.</au><au>Stroes, Erik S. G.</au><au>Groen, Albert K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)</atitle><jtitle>Lipids in health and disease</jtitle><stitle>LIPIDS HEALTH DIS</stitle><addtitle>Lipids Health Dis</addtitle><date>2020-05-11</date><risdate>2020</risdate><volume>19</volume><issue>1</issue><spage>91</spage><epage>91</epage><pages>91-91</pages><artnum>91</artnum><issn>1476-511X</issn><eissn>1476-511X</eissn><abstract>Background Epidemiological studies substantiated that subjects with elevated lipoprotein(a) [Lp(a)] have a markedly increased cardiovascular risk. Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) lowers both LDL cholesterol (LDL-C) as well as Lp(a), albeit modestly. Effects of PCSK9 inhibition on circulating metabolites such as lipoprotein subclasses, amino acids and fatty acids remain to be characterized. Methods We performed nuclear magnetic resonance (NMR) metabolomics on plasma samples derived from 30 individuals with elevated Lp(a) (> 150 mg/dL). The 30 participants were randomly assigned into two groups, placebo (N = 14) and evolocumab (N = 16). We assessed the effect of 16 weeks of evolocumab 420 mg Q4W treatment on circulating metabolites by running lognormal regression analyses, and compared this to placebo. Subsequently, we assessed the interrelationship between Lp(a) and 14 lipoprotein subclasses in response to treatment with evolocumab, by running multilevel multivariate regression analyses. Results On average, evolocumab treatment for 16 weeks resulted in a 17% (95% credible interval: 8 to 26%, P < 0.001) reduction of circulating Lp(a), coupled with substantial reduction of VLDL, IDL and LDL particles as well as their lipid contents. Interestingly, increasing concentrations of baseline Lp(a) were associated with larger reduction in triglyceride-rich VLDL particles after evolocumab treatment. Conclusions Inhibition of PCSK9 with evolocumab markedly reduced VLDL particle concentrations in addition to lowering LDL-C. The extent of reduction in VLDL particles depended on the baseline level of Lp(a). Our findings suggest a marked effect of evolocumab on VLDL metabolism in subjects with elevated Lp(a).</abstract><cop>LONDON</cop><pub>Springer Nature</pub><pmid>32393252</pmid><doi>10.1186/s12944-020-01280-0</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-3878-9196</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1476-511X |
| ispartof | Lipids in health and disease, 2020-05, Vol.19 (1), p.91-91, Article 91 |
| issn | 1476-511X 1476-511X |
| language | eng |
| recordid | cdi_proquest_journals_2404425562 |
| source | MEDLINE; Springer Online Journals Complete; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; PubMed Central; Springer Nature OA/Free Journals; Free Full-Text Journals in Chemistry |
| subjects | Aged Amino acids Analysis Antibodies, Monoclonal, Humanized - therapeutic use Apolipoproteins Biochemistry & Molecular Biology Cardiovascular diseases Cholesterol Cholesterol, HDL - blood Cholesterol, LDL - antagonists & inhibitors Cholesterol, LDL - blood Cholesterol, VLDL - antagonists & inhibitors Cholesterol, VLDL - blood Clinical trials Drug dosages Epidemiology Evolocumab Fasting Fatty acids Female Gene Expression Heart surgery Humans Hyperlipidemias - blood Hyperlipidemias - diagnosis Hyperlipidemias - drug therapy Hyperlipidemias - genetics Hypolipidemic Agents - therapeutic use Kexin Life Sciences & Biomedicine Lipid Metabolism - drug effects Lipids Lipoprotein A Lipoprotein(a) - antagonists & inhibitors Lipoprotein(a) - blood Lipoproteins Lipoproteins (very low density) Low density lipoprotein Low density lipoproteins Magnetic Resonance Spectroscopy Male Metabolism Metabolites Metabolome Metabolomics Middle Aged Monoclonal antibodies Multivariate Analysis NMR Nonsteroidal anti-inflammatory drugs Nuclear magnetic resonance Nutrition & Dietetics Patients PCSK9 antibodies PCSK9 Inhibitors Proprotein Convertase 9 - blood Proprotein Convertase 9 - genetics Proprotein convertases Science & Technology Substance abuse treatment Subtilisin Trans fatty acids Triglycerides Triglycerides - antagonists & inhibitors Triglycerides - blood Variables VLDL |
| title | Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T19%3A11%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Metabolic%20effects%20of%20PCSK9%20inhibition%20with%20Evolocumab%20in%20subjects%20with%20elevated%20Lp(a)&rft.jtitle=Lipids%20in%20health%20and%20disease&rft.au=Zhang,%20Xiang&rft.date=2020-05-11&rft.volume=19&rft.issue=1&rft.spage=91&rft.epage=91&rft.pages=91-91&rft.artnum=91&rft.issn=1476-511X&rft.eissn=1476-511X&rft_id=info:doi/10.1186/s12944-020-01280-0&rft_dat=%3Cgale_proqu%3EA627444250%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2404425562&rft_id=info:pmid/32393252&rft_galeid=A627444250&rft_doaj_id=oai_doaj_org_article_304998e60c55467cab6966bfd00b82d0&rfr_iscdi=true |